Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Roche 2021 results
Roche 2021 results Basel, 3 February 2022 3
Slide 4: Group - Severin Schwan
Group Severin Schwan Chief Executive Officer
Slide 5: 2021 performance, Outlook
2021 performance Outlook 5
Slide 6: Strong year for new products in Pharma and Diagnostics
2021: Strong year for new products in Pharma and Diagnostics Strong Group sales up +9% despite COVID-19 and biosimilars • Pharma (+3%) with continuously improving quarterly sales growth • Diagnostics (+29%) with strong growth in the base business Profit and Cash: • Core EPS growth +6% (incl. accreti
Slide 7: Guidance fully achieved
2021: Guidance fully achieved Targets for 2021 FY 2021 Group sales growth1 Low- to mid-single digit +9% Core EPS growth1 Broadly in line with sales growth +6% Dividend outlook Further increase dividend in Swiss francs2 CHF 9.30 1 At Constant Exchange Rates (CER); 2 2021 dividend as proposed by the B
Slide 8: Successfully managing the transition in volatile environment
2021: Successfully managing the transition in volatile environment Significant sales growth despite Bx impact Efficiency gains & investment into future Group Group Sales Core OP CHFm (CER) CHFm (CER) + 155 + 1,101 - 216 - 75 - 1,517 + 1,597 2 + 5,725 -4,509 + 4,064 -4,354 22,416 63,740 21,526 +4% +9
Slide 9: Sales growth driven by both Divisions
2021: Sales growth driven by both Divisions 2021 2020 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 45.0 44.5 1 3 Diagnostics Division 17.8 13.8 29 29 Roche Group 62.8 58.3 8 9 CER=Constant Exchange Rates 9
Slide 10: Growing topline during biosimilar impact & COVID-19
2021: Growing topline during biosimilar impact & COVID-19 +9% +9% +7% +5% +5% +4% +1% CHFbn 61.5 62.8 56.8 58.3 50.6 53.3 48.1 Biosimilar impact COVID-19 impact 2015 2016 2017 2018 2019 2020 2021 Growth rates at CER (Constant exchange Rates) 10
Slide 11: Strong underlying business performance for both divisions
Strong underlying business performance for both divisions Pharma Diagnostics Quarterly sales evolution 2020-2021 Quarterly sales evolution 2020-2021 % CER % CER +60% +60% +55% +50% +48% +50% +50% +40% +35% +40% +40% +32% +29% +28% +31% +30% +25% +30% +20% +19% +23% +30% +18% +17% +18% +20% +24% +14%
Slide 12: Core EPS growth ahead of guidance and excellent cash flow
2021: Core EPS growth ahead of guidance and excellent cash flow Core operating profit Core EPS Operating free cash flow 36.6% 36.9% 34.0% % of sales 30.9% 34.9% 25.4% +4% at CER +6% at CER +34% at CER CHFbn 21.9 CHF CHFbn 19.81 19.4 22.5 20.9 21.5 20.16 19.16 14.8 2019 2020 2021 2019 2020 2021 2019
Slide 13: 2021 performance, Outlook
2021 performance Outlook 13
Slide 14: Uncertainty on Delta & Omicron and evolution of COVID
Uncertainty on how Delta & Omicron will impact medium-term and evolution of COVID Example scenarios and key assumption drivers (not exhaustive) Scenario A: COVID steady state ● Delta & Omicron drive near-term caution and higher Global Monthly Reported Cases vaccination rates ● Vaccine and/or disease
Slide 15: 2022: Extensive newsflow and upcoming launches
2022: Extensive newsflow and upcoming launches Pharma pipeline Event Diagnostics pipeline Event Susvimo in nAMD Launch BenchMark ULTRA PLUS Automated immunohistochemistry/in situ Launch Vabysmo in DME/nAMD Launch hybridization advanced staining platform Polivy in 1L DLBCL Launch DP600 Launch High ca
Slide 16: 2022 sales outlook
2022 sales outlook Sales drivers1 Pharma: New products with accelerating growth Diagnostics: Base business with strong growth • Guidance stable to low-single digit group sales growth • Group sales to grow high-single AHR2 biosimilars: Roughly CHF -2.5 bn sales digit if COVID-19 sales and AHR erosion
Slide 17: 2022 outlook
2022 outlook Group sales growth1 • Stable to low-single digit • Low- to mid-single digit (including accretion of Core EPS growth1 4.4%p from share repurchase) Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 17
Slide 18: Pharmaceuticals Division - Bill Anderson
Pharmaceuticals Division Bill Anderson CEO Roche Pharmaceuticals
Slide 19: Pharmaceuticals Division sales
2021: Pharmaceuticals Division sales New products compensating for biosimilar impact during COVID-19 pandemic 2021 2020 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 45,041 44,532 1 3 United States 22,505 23,647 -5 -2 Europe 8,876 8,198 8 7 Japan 4,506 3,765 20 26 International 9,154 8,922
Slide 20: Pharmaceuticals Division core results
2021: Pharmaceuticals Division Higher COVID-19 related cost of sales and R&D investments impacting core operating profit 2021 2021 vs. 2020 CHFm % sales CER growth Sales 45,041 100 3% Royalties & other op. inc. 2,969 6.6 54% Cost of sales -9,449 -21.0 18% COGS + PC: +20% M&D -6,517 -14.5 0% R&D -11,
Slide 21: Continued portfolio rejuvenation
2021: Continued portfolio rejuvenation Ronapreve n/a Hemlibra 41% Ocrevus 19% Actemra / RoActemra 27% Tecentriq 24% Evrysdi >500% Phesgo >500% Kadcyla 16% Alecensa 18% Perjeta 4% Enspryng >500% Xolair 5% Polivy 48% Gazyva 9% Esbriet -5% US Lucentis -4% Europe Tamiflu -78% Herceptin -28% Japan MabThe
Slide 22: Oncology still impacted by biosimilars & COVID-19
2021: Oncology still impacted by biosimilars & COVID-19 YoY CER growth HER2 franchise Phesgo (>500%) • Kadcyla (+16%) with growth in all regions due to adjuvant BC HER2 franchise Herceptin Perjeta (+4%) -3% • Perjeta (+4%) growth cannibalized by Phesgo launch Kadcyla (+16%) Tecentriq Tecentriq +24%
Slide 23: Tecentriq overview: Adjuvant program to read out in 2022
Tecentriq overview: Adjuvant program to read out in 2022 US approval for adjuvant NSCLC achieved only 6 months after readout Tecentriq Q4 update CHFm YoY CER growth • Q4 US sales impacted by label changes 1,000 900 +23% Lung franchise (NSCLC, SCLC) +31% +17% 800 +26% +49% +35% • EU: Growth driven by
Slide 24: Tiragolumab pivotal trials initiated, readouts in 2022
Tiragolumab with 9 pivotal trials initiated, 4 readouts in 2022 Positive OS data in 1L NSCLC presented Ph II (CITYSCAPE) results: Ph III trial program for tiragolumab Tiragolumab + Tecentriq in 1L PDL1+ NSCLC (n=58) Overall survival for TPS≥ 50% Indication Ph 1 Ph 2 Ph 3 1L NSCLC: PD-L1 high SKYSCRA
Slide 25: Hematology: Improving the standard of care in DLBCL and FL
Hematology: Improving the standard of care in DLBCL and FL Ph III (POLARIX) results in 1L DLBCL Ph I mosunetuzumab step up dosing First positive study in 20 years in heavily pretreated R/R FL Progression free survival (PFS) Best percentage change from baseline in tumor SPD Tilly et al, NEJM 2021 • P
Slide 26: Hematology franchise: Ph III combination development in NHL
Hematology franchise: Ph III combination development in NHL DLBCL FL Polivy+R-CHP, a new SOC in a curative setting Gazyva established as SOC in 1L iNHL with estimated 3 yrs longer mPFS than Rituxan 1L R/R 3L+ CHOP benda 1L 2L+ 3L+ chemo benda R-CHOP R+benda R+chemo R+benda Polivy+ Polivy+ G+chemo G+
Slide 27: Hemophilia A franchise: Hemlibra new standard of care
Hemophilia A franchise: Hemlibra accepted as new standard of care 33% US/EU-5 patient share reached CHFm YoY CER growth Hemophilia Q4 update 1,000 • >14,500 patients treated globally 900 +38% 800 +37% +58% • Hemlibra continues to penetrate across all patient types +33% • Ph III (HAVEN 6) interim res
Slide 28: Immunology franchise moved by COVID-19
Immunology franchise moved by COVID-19 Immunology Q4 update CHFm YoY CER growth 2,500 • Ph III (ALLEGORY) Gazyva in SLE started in Q4 21 +12% 0% -2% +7% Actemra (+27%) 2,000 • WHO recommends IL-6 inhibitors for hospitalized COVID-19 patients 1,500 with >500.000 patients treated in 2021 • Remains lea
Slide 29: MS franchise: Ocrevus US market share increases
MS franchise: Ocrevus total US market share increases to 30% MS late stage development programs progressing well CHFm YoY CER growth 1,500 Q4 update +25% +7% 1,250 +37% +16%+31% • US/EU still impacted by COVID-19 +38% +55% +10% 1,000 +59% +48% +12% • Higher dose Ocrevus: Ph III (MUSETTE) in RMS full
Slide 30: SMA franchise: Evrysdi launches
SMA franchise: Evrysdi with strong US and EU launches Most prescribed treatment in the US with >20% share; Germany with ~30% share Q4 update CHFm YoY CER growth 250 • ~4,500 patients treated world wide (commercial, clinical trials, +347% compassionate use) 200 • US: Increasing share of naive patient
Slide 31: Ophthalmology franchise: Building a global business
Ophthalmology franchise: Building a global business Improved patient outcomes and reduced treatment burden Susvimo maintained vision through week 72 with Vabysmo achieved 75-80% of patients on ≥Q12W dosing, ~95 % of patients maintaining 6 month dosing ~50% on ≥Q16W dosing at year 1 Ph III (ARCHWAY)
Slide 32: Strong portfolio rejuvenation and diversification
Strong portfolio rejuvenation and diversification 3 NME launches expected in 2022 Diversification of Roche sales FY 2016 FY 2021 CHF 50.6bn CHF 62.8bn AHR AHR Diagnostics Oncology Other pharma AHR Ophthalmology Neuroscience Infectious diseases Hemophilia A Immunology AHR=Avastin, Herceptin, Rituxan/
Slide 33: 2021: Key late-stage newsflow
2021: Key late-stage newsflow* Compound Indication Milestone Xofluza Healthy patients; High risk patients; Post exposure EU approval Evrysdi SMA type 1/2/3 EU approval Vabysmo DME/nAMD US/EU joint filing (DME+AMD) Regulatory Tecentriq 1L PDL1+ NSCLC EU approval Venclexta + azacitidine 1L unfit AML E
Slide 34: 2022: Key late-stage newsflow
2022: Key late-stage newsflow* Compound Indication Milestone Vabysmo nAMD/DME US/EU approval Susvimo nAMD EU approval mosunetuzumab 3L+ FL US/EU approval Regulatory Tecentriq Adjuvant NSCLC EU approval Hemlibra Mild to moderate hemophilia A EU approval Polivy + R-CHP 1L DLBCL EU/US approval glofitam
Slide 35: Diagnostics Division - Thomas Schinecker
Diagnostics Division Thomas Schinecker CEO Roche Diagnostics
Slide 36: Diagnostics Division sales
2021: Diagnostics Division sales Sales increase of +29% driven by COVID-19 testing and base business 2021 2020 Change in % CHFm CHFm CHF CER Diagnostics Division 17,760 13,791 29 29 Core Lab 7,473 6,194 21 21 Molecular Lab 4,812 3,760 28 29 Point of Care 2,583 1,079 139 138 Diabetes Care 1,690 1,670
Slide 37: Diagnostics Division sales growth by quarter
Diagnostics Division sales growth by quarter Strong COVID-19 sales and base business growth 55% Diagnostics Division sales growth YoY 48% Base business growth YoY1 28% 31% 18% 17% 18% 9% 5% 2% 11% 1% -2% 8% -5% Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 -17% COVID- Q1: Q2: Q3: Q4: Q1: Q2: Q3: Q
Slide 38: Diagnostics Division regional sales
2021: Diagnostics Division regional sales Very strong growth in all regions North America +16% EMEA1 ~25% of divisional sales +37% ~42% of divisional sales Asia Pacific Latin America +29% +48% ~27% of divisional sales ~6% of divisional sales Growth rates at CER (Constant exchange Rates); 1 Europe, M
Slide 39: Diagnostics Division highlights
2021: Diagnostics Division highlights Very strong growth across all businesses CHFbn YoY CER growth • Immunodiagnostics (+25%) Core Lab1 +21% • Clinical Chemistry (+16%) • Virology (+27%) Molecular Lab +29% • POC Molecular (+271%) Point of Care +138% • POC Immunodiagnostics (+310%) • Blood glucose m
Slide 40: Diagnostics Division core results
2021: Diagnostics Division Strong core operating profit growth driven by volume growth 2021 2021 vs. 2020 CHFm % sales CER growth Sales 17,760 100 29% Royalties & other op. inc. 80 0.5 30% Cost of sales -8,689 -48.9 34% M&D -2,927 -16.5 8% R&D -1,756 -9.9 14% G&A -543 -3.1 7% Core operating profit 3
Slide 41: US EUA for COVID-19 At-Home Test
US emergency use authorization for COVID-19 At-Home Test Excellent performance validated by independent NIH clinical trial Lateral flow testing principle NIH study result Sample pad Conjugate pad Nitrocellulose membrane Absorption pad SARS-CoV-2 Flow T C 95.3% Sensitivity 100% Specificity Coloured t
Slide 42: SARS-CoV-2 & Flu A/B Rapid Antigen Test
SARS-CoV-2 & Flu A/B Rapid Antigen Test1 Rapid diagnosis & differentiation between respiratory viruses Lateral flow testing principle Excellent Performance2 Sample pad Conjugate pad Nitrocellulose membrane Absorption pad Flow SARS-CoV-2 Influenza A Influenza B A B S C 84.85% 81.16% 100% Sensitivity
Slide 43: cobas 5800 fully automated PCR system
cobas® 5800 fully automated low to mid throughput PCR system1 Strengthens further industry leading molecular portfolio cobas® 5800 cobas® 6800 cobas® 8800 cobas® PRIME Integrated Molecular Systems Molecular Labs, Core Labs, Blood Banks GenMark ePlex cobas® Liat Syndromic Point of Testing Care Hospit
Slide 44: cobas pulse and cobas infinity edge SMART
cobas® pulse1 and cobas® infinity edge SMART Building an ecosystem for clinical decision support 3rd Party Apps3 Clinical decision Communication / support Documentation Offline test entry Digital Biomarkers Hospitals Pharmacies Sensor Reader ... GPs cobas® pulse cobas® infinity edge SMART 2 Utilisat
Slide 45: AVENIO tumor tissue comprehensive genomic profiling panel
AVENIO tumor tissue comprehensive genomic profiling panel Decentralizing the FoundationOne® assay Comprehensive Genomic Profiling • Equivalent to FoundationOne® CDx Panel EGFR KRAS • Detects 4 classes of genomic alterations: BRAF – Substitutions ALK – Insertions and deletions ERBB2 Hot spot – Rearra
Slide 46: NAVIFY Oncology Hub
NAVIFY® Oncology Hub Empowering more efficient and effective clinical decisions From stand-alone records… …to intelligent insights Aggregated patient data across Fragmented patient data systems Fast access to data via one Slow access to relevant data central workspace Difficult to share information
Slide 47: Key launches 2021
Key launches 2021 Area Product Description Market1 cobas® pure integrated solutions Low-to-medium volume SWA CE Core Lab cobas® pro integrated solutions New high throughput configurations of the cobas pro instrument US & CE Point of Care cobas® pulse Successor of Accu-Chek® Inform II CE Instruments
Slide 48: Key launches 2022
Key launches 2022 Area Product Description Market Automated immunohistochemistry/in situ hybridization (ISH) advanced staining platform with Pathology Lab BenchMark ULTRA PLUS US & CE enhanced software capabilities, workflow and testing efficiency DP600 High capacity pathology slide scanner for high
Slide 49: Finance - Alan Hippe
Finance Alan Hippe Chief Financial Officer
Slide 50: 2021 results, cash and balance sheet, Outlook
2021 results Focus on cash and balance sheet Outlook 50
Slide 51: 2021: Highlights
2021: Highlights Business • Group sales growth of +9%1 , growing through the biosimilar impact2 and COVID-19 uncertainties • Core operating profit up +4%1 and Core EPS growth +6% (incl. accretion of 0.4%) supported by favorable tax development • Dividend in Swiss francs further increased Cash flow •
Slide 52: Successfully managing the transition in volatile environment
2021: Successfully managing the transition in volatile environment Significant sales growth despite Bx impact Efficiency gains & investment into future Group Group Sales Core OP CHFm (CER) CHFm (CER) + 155 + 1,101 - 216 - 75 - 1,517 + 1,597 2 + 5,725 -4,509 + 4,064 -4,354 22,416 63,740 21,526 +4% +9
Slide 53: 2021: Group performance
2021: Group performance Sales growth of +9%, core operating profit up +4%, core EPS growth of +6% 2021 2020 Change in % CHFm CHFm CHF CER Sales 62,801 58,323 8 9 Core operating profit 21,897 21,536 2 4 as % of sales 34.9 36.9 Core net income 18,071 17,378 4 6 as % of sales 28.8 29.8 Core EPS (CHF) 1
Slide 54: 2021: Core EPS development
2021: Core EPS development Operations growth and tax rate change are main drivers for higher Core EPS +6.0% CHF + 3.3 p + 4.4 p -0.4 p -1.3 p 20.51 19.35 2020 Operations Gains/losses on Effective tax Rate Other* 2021 equity Change securities At Constant Exchange Rates (CER); incl. accretion from sha
Slide 55: Group Core operating performance
2021: Group Core operating performance Core operating profit growth of +4% 2021 2021 vs. 2020 CHFm abs. CER CER growth Sales 62,801 +5,435 9% Royalties & other op. inc. 3,049 +1,075 53% Cost of sales -18,138 -3,704 25% M&D -9,444 -211 2% R&D -13,708 -1,734 14% G&A -2,663 +30 -1% Core operating profi
Slide 56: 2021: Group sales
2021: Group sales CER sales up by +9% mainly driven by Diagnostics Division -2% +7% +4% +26% +29% +9% +8% Pharma Division +29% +3% -957 +4,064 5,435 4,478 +339 +993 +557 -518 1 United States Europe Intl. Chugai Dia Division Group Fx ¹ Group (Japan) CHF At Constant Exchange Rates (CER); 1 avg. full y
Slide 57: Royalties and other operating income
2021: Royalties and other operating income Higher income driven by profit share from US income of casirivimab+imdevimab CHFm +257 +754 +60 -42 3,049 2,020 Royalties and other operating income increased by +53% at CER 2020 Royalty income Out-licensing Other operating Income from 2021 income income in
Slide 58: Group Core cost of sales
2021: Group Core cost of sales (COS) Increase due to volume growth, incremental production costs for Ronapreve & AT-527 and change in the Pharma/Diagnostics sales mix 761 807 18,478 18,264 615 -214 2,185 -449 CHFm 14,559 Pharma Division’s proportion of Group sales declines from 76% to 72% COS as % o
Slide 59: Core operating profit and margin
2021: Core operating profit and margin % of sales 43.3% 43.7% 41.2% 36.6% 36.9% 34.9% -2.2%p¹ -1.7%p¹ 22.1% +4%¹ 18.6% 15.2% 22,479 21,536 21,897 -2%¹ +3.5%p¹ CHFm 21,015 19,477 18,548 +54%¹ 3,925 1,966 2,564 2019 2020 2021 Roche Group Pharma Division Diagnostics Division 1 At Constant Exchange Rate
Slide 60: Core net financial result
2021: Core net financial result Higher net financial expenses driven by equity securities and partially offset by lower interest expenses CHFm • Net financial expense increased by -35% at CER • Interest expenses1 decreased by +20% at CER -564 -751 -257 +95 +21 -20 -26 2020 Equity Net interest FX G/L
Slide 61: Core tax rate
2021: Core tax rate Tax rate before resolution of tax disputes improves slightly to 17.8% -1.5%p -0.8%p -3.3%p 18.6 17.8 % 17.1 14.5 2020 2020 2021 2021 As reported Resolution of Tax Before Resolution of Tax development Before Resolution of Resolution of Tax As reported Disputes 2020 Tax Disputes (e
Slide 62: Non-core items and IFRS income
2021: Non-core items and IFRS income Non-core operating expenses increasing due to Accutane provision release in 2020 and higher expenses for global restructuring plans 2020 2021 Change in % CHFm CHFm CHFm CHF CER Core operating profit 21,536 21,897 361 +2 +4 Global restructuring plans -909 -1,362 -
Slide 63: 2021: Group performance
2021: Group performance Sales growth of +9%, core operating profit up +4%, core EPS growth of +6% 2021 2020 Change in % CHFm CHFm CHF CER Sales 62,801 58,323 8 9 Core operating profit 21,897 21,536 2 4 as % of sales 34.9 36.9 Core net income 18,071 17,378 4 6 as % of sales 28.8 29.8 Core EPS (CHF) 1
Slide 64: 2021 results, cash and balance sheet, Outlook
2021 results Focus on cash and balance sheet Outlook 64
Slide 65: Operating free cash flow and margin
2021: Operating free cash flow and margin Higher OFCF of +34% driven by lower investments in Intangible Assets and higher OP, net of cash adjustments 42.3% % of sales 36.9% 34.0% 31.1% 30.9% 25.4% +6.1%p¹ +5.7%p¹ 19.0% 11.4% 7.4% +7.5%p¹ +34%¹ 20,921 20,536 CHFm 19,411 +23%¹ 16,639 14,815 13,853 +11
Slide 66: Operating Free Cash Flow
2021: Operating Free Cash Flow Higher OFCF of +34% driven by lower investments in Intangible Assets and higher OP, net of cash adjustments CHFm +2,292 -433 +1,010 -240 +1,967 19,411 14,815 OFCF higher by +34%/+5,029m at CER 2020 OP, net of cash NWC Investments Investments Foreign 2021 adjustments mo
Slide 67: Net debt development
2021: Net debt development Net debt higher by CHF -16.3bn compared to previous YE 2020 due to share repurchase Free Cash Flow CHF 15.7bn CHFbn vs. 10.9bn in 2020 -3.7 Taxes -3.3 Treasury -0.4 +19.4 -32.0 -1.9 Dividends paid -8.1 M&A & All. trans. -2.4 Curr. Transl. & Other -1.1 Trans. own eq. instr.
Slide 68: Balance sheet December 2021
Balance sheet 31 December 2021 Equity ratio at 31% (YE 2020: 46%) and net debt to assets at 20% (YE 2020: 2%) % change in CER vs % change in CER vs CHFbn 31 Dec 2020 31 Dec 2020 92.3 +7% 92.3 +7% Cash and 86.1 86.1 13.0 +8% marketable 12.3 14% Current securities 14% 25.4 38.4 22.6 liabilities +49% 2
Slide 69: 2021 results, cash and balance sheet, Outlook
2021 results Focus on cash and balance sheet Outlook 69
Slide 70: Currency impact
2021: Currency impact CHF / USD -7% -6% -4% -3% 0.97 0.97 0.95 0.94 In 2021 impact1 is (%p): Average YTD 2020 Q1 HY Sep FY 0.91 0.91 0.91 0.90 Average YTD 2021 YTD 0.89 0.90 0.93 0.92 0.90 0.91 0.92 0.91 0.92 0.92 0.92 0.92 Sales -4 -3 -2 -1 Monthly avg fx rates 2021 Core operating -5 -2 CHF / EUR p
Slide 71: Core EPS basis for outlook
2021: Core EPS Core EPS 2021 of CHF 20.05 is basis for Core EPS outlook 2022 at CER CHF +0.07 +0.24 19.74 19.81 19.81 20.05 Core EPS 2021 Share Core EPS 2021 2021 fx losses Core EPS 2021 as reported repurchase as reported Core EPS basis for Outlook (excl. repurchase) impact impact Core EPS growth 20
Slide 72: Core EPS impacted by share repurchase
Core EPS impacted by share repurchase +4.8% ~ -0.34 20.69 +1.22 19.74 19.81 +0.07 2021: +0.4% 2022: +4.4% Core EPS 2021 2021 Share Core EPS 2021 Number of Cost of financing Core EPS 2021 at Reported repurchase impact at Reported Shares change (assumption) after repurchase (excl. repurchase) impact i
Slide 73: 2022 outlook
2022 outlook Group sales growth1 • Stable to low-single digit • Low- to mid-single digit (including accretion of Core EPS growth1 4.4%p from share repurchase) Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 73
Slide 74: Doing now what patients need next
Doing now what patients need next
Slide 75: Roche Group development pipeline
Roche Group development pipeline 75
Slide 76: Changes to the development pipeline
Changes to the development pipeline Q4 2021 update New to phase I New to phase II New to phase III New to registration 5 NMEs: 1 NME: 1 NME: 1 NME (EU and US): RG6129 HLA-A2-MAGE-A4 x CD3 – solid tumors RG6179 NME - DME RG6356 delandistrogene moxeparvovec (SRP- RG7828 mosunetuzumab - 3L+FL RG6289 NM
Slide 77: Roche Group development pipeline
Roche Group development pipeline Phase I (45 NMEs + 12 AIs) Phase II (21 NMEs + 12 AIs) RG6007 HLA-A2-WT1 x CD3 AML CHU FIXa x FX haemophilia tiragolumab + T NSCLC RG6026 glofitamab monotherapy and combos heme tumors CHU glypican-3 x CD3 solid tumors tiragolumab + T + chemo 1L non-squamous NSCLC RG6
Slide 78: Roche Group development pipeline
Roche Group development pipeline Phase III (11 NMEs + 40 AIs) Registration US & EU (3 NMEs + 8 AIs) Kadcyla + T 2L+ HER-2+ PD-L1+ mBC Venclexta r/r MM t(11:14) RG6013 Hemlibra3 mild to moderate hemophilia A RG3502 RG7601 Kadcyla + T HER-2+ eBC high-risk Venclexta + azacitidine 1L MDS RG6396 Gavreto2
Slide 79: NME submissions and their additional indications
NME submissions and their additional indications Projects in phase II and III semorinemab RG6100 Alzheimer’s brain shuttle glofitamab + chemo RG6026 RG6102 gantenerumab 2L DLBCL New Molecular Entity (NME) Metabolism Alzheimer’s Additional Indication (AI) Neuroscience tiragolumab + T crovalimab bepra
Slide 80: AI submissions for existing products
AI submissions for existing products Projects in phase II and III RG6152 Xofluza direct transmission Xofluza New Molecular Entity (NME) Metabolism RG6152 influenza, pediatric Additional Indication (AI) Neuroscience (0-1 year) Oncology / Hematology Ophthalmology Immunology Other Xolair Infectious Dis
Slide 81: Major pending approvals 2021
Major pending approvals 2021 US EU China Japan-Chugai Evrysdi Tecentriq Tecentriq Vabysmo (faricimab) SMA presymptomatic pediatric RG7446 NSCLC adj RG7446 NSCLC adj RG7716 DME RG7916 <2months Filed June 2021 Filed June 2021 Filed June 2021 Filed Nov 2021 Susvimo (PDS with ranibizumab) Rozlytrek Vaby
Slide 82: Major granted approvals 2021 and 2022 YTD
Major granted approvals 2021 and 2022 YTD US EU China Japan-Chugai Alecensa (BFAST) Xofluza Xofluza Polivy RG7853 1L NSCLC ALK+ RG6152 influenza, otherwise healthy RG6152 influenza, otherwise healthy RG7596 r/r DLBCL Jan 2021 Jan 2021 April 2021 March 2021 Actemra Xofluza Xofluza Evrysdi RG1569 SSc-
Slide 83: Doing now what patients need next
Doing now what patients need next